Brief: Mabion And Novavax Terminates Research Cooperation On SARS CoV-2 RS Wuhan Variant
Oct 18 (Reuters) - Mabion SA MABP.WA :
* DECIDES TO TERMINE STATEMENT OF WORK 8 WITH NOVAVAX
* FOLLOWING TERMINATION, BOTH PARTIES DECIDES TO STOP CARRY
OUT
RESEARCH ON SARS COV-2 RS
* SAID RESEARCH REGARDED WUHAN VARIANT OF SARS COV-2 RS
* COMPANY STILL TO CARRY OUT RESEARCH ON SARS COV-2 RS
OMICRON
VARIANT
* NOVAVAX INFORMED ABOUT NO NEED TO CONTINUE RESEARCH ON
WUHAN
VARIANT
Source text for Eikon: ID:nEM1j3HMQa
Further company coverage: MABP.WA NVAX.O
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; 48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects